Central polydactyly of fingers

Summary

Central polydactyly of fingers (MONDO:0017456) is a disease and 1 clinical trial. A subtype of non-syndromic polydactyly — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	central polydactyly of fingers
Mondo ID	MONDO:0017456
Orphanet	295004
ICD-11	243366415
SNOMED CT	205130008
UMLS	C0431903
MedGen	609220
GARD	0021200
Is cancer (heuristic)	no

Also known as: central polydactyly of hand · mesoaxial polydactyly · mesoaxial polydactyly of fingers · mirror hand

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › polydactyly › non-syndromic polydactyly › central polydactyly of fingers

Related subtypes (9): polysyndactyly 4, synpolydactyly type 1, synpolydactyly type 2, preaxial polydactyly of fingers, postaxial polydactyly of fingers, Preaxial polydactyly of toes, megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome, postaxial polydactyly, mirror-image polydactyly

Subtypes (2): central polydactyly of fingers, unilateral, central polydactyly of fingers, bilateral

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05396053	Not specified	COMPLETED	Mirror Therapy Versus CIMT on Hand Function in Cerebral Palsy